fusidic acid profile

terephthalylidene dicamphor sulfonic acid: structure given in first source; abreviated as TDSA; FDA approved 2006 as component of Anthelios SX along with avobenzone and octocrylene [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Fusidic Acid: An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed). It acts by inhibiting translocation during protein synthesis. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fusidic acid : A steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	146382
CHEMBL ID	3989850
CHEBI ID	135830
MeSH ID	M0008910
PubMed CID	3000226
CHEMBL ID	374975
CHEBI ID	29013
SCHEMBL ID	25646
MeSH ID	M0008910

Synonym
mexoryl sx
ecamsule
terephthalylidene dicamphor sulfonic acid
CHEBI:135830
bicyclo(2.2.1)heptane-1-methanesulfonic acid, 3,3'-(1,4-phenylenedimethylidyne)bis(7,7-dimethyl-2-oxo-
unii-m94r1pm439
(e-e )-3,3'-(1,4-phenylenedimethylidene)bis(2-oxobornane-10-sulfonic acid)
bicyclo(2.2.1)heptane-1-methanesulfonic acid, 3,3'-(1,4-phenylenedimethylidyne)bis(7,7-dimethyl-2-oxo-, (1s-(1alpha(1r,4r),4beta))-
hsdb 8476
ec 410-960-6
ecamsule [usan:usp:inn]
m94r1pm439 ,
(+-)-(3e,3'e)-(p-phenylenedimethylidyne)bis(2-oxo-10-bornanesulfonic acid)
(+-)-(3e,3'e)-3,3'-(p-phenylenedimethylidyne)bis(2-oxo-10-bornanesulfonic acid)
3,3'-(1,4-phenylenedimethylidyne)bis(7,7-dimethyl-2-oxobicyclo(2.2.1)heptane-1-methanesulfonic acid)
nsc 760054
nsc-760054
90457-82-2
mexoryl
HEAHZSUCFKFERC-UHFFFAOYSA-N
terephthalylidenedicamphor sulphonic acid
terephthalylidenedicamphorsulfonic acid
terephthalylidenedicamphorsulphonic acid
BCP16962
[3-[[4-[[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanylidene]methyl]phenyl]methylidene]-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic acid
CHEMBL3989850
[(3e)-3-[[4-[(z)-[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanylidene]methyl]phenyl]methylidene]-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic acid
[(3e)-3-[[4-[(e)-[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanylidene]methyl]phenyl]methylidene]-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic acid
MLS002207094
(2z)-2-[(3alpha,4alpha,5alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17z)-16-(acetyloxy)-3,11-dihydroxy-4,8,10,14-tetramethylgonan-17-ylidene]-6-methylhept-5-enoic acid
29-nordammara-17(20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, (3alpha,4alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17z)-
29-nor-8alpha,9beta,13alpha,14beta-dammara-17(20),24-dien-21-oic acid, 3alpha,11alpha,16beta-trihydroxy-, 16-acetate, (z)-
3alpha,11alpha,16beta-trihydroxy-29-nor-8alpha,9beta,13alpha,14beta-dammara-17(20),24-dien-21-oic acid 16-acetate
nsc 56192
acido fusidico [inn-spanish]
fusidic acid [usan:inn:ban]
fucithalmic
acidum fusidicum [inn-latin]
einecs 230-256-0
c.a.s. 62,602; diethanolamine fusidate
acide fusidique [inn-french]
c.a.s. 62,602
fusidine
nsc56192
3.alpha.,16.beta.-trihydroxy-29-nor-8.alpha.,9.beta.,13.alpha.,14.beta.-dammara-17(20),24-dien-21-oic acid 16-acetate
ramycin
sq 16603
fucidic acid
nsc-56192
29-nordammara-17(20), 16-(acetyloxy)-3,11-dihydroxy-, (3.alpha.,4.alpha.,8.alpha.,9.beta.,11.alpha.,13.alpha.,14.beta.,16.beta.,17z)-
fucidin acid
29-nor-8.alpha.,13.alpha.,14.beta.-dammara-17(20),24-dien-21-oic acid, 3.alpha.,11.alpha.,16.beta.-trihydroxy-, 16-acetate, (z)-
acid, fusidic
D04281
fusidic acid (usan/inn)
PRESTWICK2_000390
MLS001332649 ,
smr000857101
MLS001332650
sq 16,603
(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetoxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methyl-hept-5-enoic acid
29-nordammara-17(20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, (3a,4a,8a,9b,11a,13a,14b,16b,17z)-
16-(acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic acid
fusidic acid
C06694
6990-06-3
DB02703
1QCA
fucidate
CHEBI:29013 ,
(2z)-2-[(17z)-16beta-acetoxy-3alpha,11alpha-dihydroxy-4alpha,8alpha,10,14beta-tetramethyl-5alpha,9beta,13alpha-gonan-17-ylidene]-6-methylhept-5-enoic acid
(-)-fusidic acid
(-)-16beta-acetoxy-3alpha,11alpha-dihydroxyfusida-17(20)z,24-diene-21-oic acid
LMPR0106040001
cem-102
taksta
anhydrous fusidic acid
CHEMBL374975
sq-16603
AKOS005146257
(2e)-2-[(3r,4s,5s,8s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid
(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid
acide fusidique
acido fusidico
acidum fusidicum
HMS2235B11
S3971
fusidinic acid
59xe10c19c ,
unii-59xe10c19c
flucidin
fusidic acid [ep monograph]
29-nordammara-17(20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, (3.alpha.,4.alpha.,8.alpha.,9.beta.,11.alpha.,13.alpha.,14.beta.,16.beta.,17z)
fusidic acid [mi]
fusidic acid [usan]
fusidic acid [who-dd]
fusidic acid [inn]
fusidic acid [ep impurity]
IECPWNUMDGFDKC-MZJAQBGESA-N
SCHEMBL25646
Q-201141
bdbm58924
cid_3000226
(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-4,8,10,14-tetramethyl-3,11-bis(oxidanyl)-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methyl-hept-5-enoic acid
(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methyl-5-heptenoic acid
F1007
mfcd00865135
DTXSID0023086 ,
fusidic acid, european pharmacopoeia (ep) reference standard
fusidic acid for peak identification, european pharmacopoeia (ep) reference standard
NCGC00485232-01
(z)-2-((3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetoxy-3,11-dihydroxy-4,8,10,14-tetramethyldodecahydro-1h-cyclopenta[a]phenanthren-17(2h,10h,14h)-ylidene)-6-methylhept-5-enoic acid
(2z)-2-[(3beta,4beta,5alpha,8alpha,9beta,11beta,13alpha,16beta,17z)-16-(acetyloxy)-3,11-dihydroxy-4,8,10,14-tetramethylgonan-17-ylidene]-6-methylhept-5-enoic acid
EX-A3797
DS-3261
fusidicacid
Q259930
(3alpha,4alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17z)-16-(acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic acid
fusidic-acid
CCG-269829
gtpl10815
cem102
HY-B1350
CS-0013095
(3alpha,4alpha,8alpha,9beta,11alpha,13alpha,147beta,167beta,17z)-16-(acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic acid
fusidic acid for peak identification
EN300-22411576
2-[(1z,2s,3as,3bs,5as,6s,7r,9as,9bs,10r,11ar)-2-(acetyloxy)-7,10-dihydroxy-3a,3b,6,9a-tetramethyl-hexadecahydro-1h-cyclopenta[a]phenanthren-1-ylidene]-6-methylhept-5-enoic acid
acido fusidico (inn-spanish)
acide fusidique (inn-french)
d06ax01
fusidic acid (ep impurity)
fusidic acid (ep monograph)
s01aa13
j01xc01
29-nordammara-17(20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, (3alpha,4alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17z)
dtxcid103086
acidum fusidicum (inn-latin)
(2z)-2-((17z)-16beta-acetoxy-3alpha,11alpha-dihydroxy-4alpha,8alpha,10,14beta-tetramethyl-5alpha,9beta,13alpha-gonan-17-ylidene)-6-methylhept-5-enoic acid

Role	Description
protein synthesis inhibitor	A compound, usually an anti-bacterial agent or a toxin, which inhibits the synthesis of a protein.
EC 2.7.1.33 (pantothenate kinase) inhibitor	An EC 2.7.1.* (phosphotransferases with an alcohol group as acceptor) inhibitor that interferes with the action of pantothenate kinase (EC 2.7.1.33).
Escherichia coli metabolite	Any bacterial metabolite produced during a metabolic reaction in Escherichia coli.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
monoterpenoid	Any terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
steroid antibiotic
3alpha-hydroxy steroid	A 3-hydroxy steroid in which the 3-hydroxy substituent is in the alpha-position.
11alpha-hydroxy steroid
sterol ester	A steroid ester obtained by formal condensation of the carboxy group of any carboxylic acid with the 3-hydroxy group of a sterol.
steroid acid	Any steroid substituted by at least one carboxy group.
alpha,beta-unsaturated monocarboxylic acid	A monocarboxylic acid in which the carbon of the carboxy group is directly attached to a C=C or C#C bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
thioredoxin glutathione reductase	Schistosoma mansoni	Potency	50.1187	0.1000	22.9075	100.0000	AID485364
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	63.0957	0.3548	28.0659	89.1251	AID504847
chromobox protein homolog 1	Homo sapiens (human)	Potency	79.4328	0.0060	26.1688	89.1251	AID540317
geminin	Homo sapiens (human)	Potency	29.0929	0.0046	11.3741	33.4983	AID624296
Guanine nucleotide-binding protein G	Homo sapiens (human)	Potency	35.4813	1.9953	25.5327	50.1187	AID624288
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Type Iii Chloramphenicol Acetyltransferase	Shigella flexneri	Ki	5.4000	5.4000	5.4000	5.4000	AID977610
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Rattus norvegicus (Norway rat)	IC50 (µMol)	17.4000	0.4000	2.7500	8.6000	AID1209456
Bile salt export pump	Rattus norvegicus (Norway rat)	Ki	2.2000	0.3000	3.1000	6.1000	AID681728
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	10.5667	0.1100	7.1903	10.0000	AID1209455; AID1443980; AID1473738
Canalicular multispecific organic anion transporter 1	Rattus norvegicus (Norway rat)	Ki	8.7000	0.8400	4.9682	10.0000	AID679020; AID679021; AID679028
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)	IC50 (µMol)	52.0000	0.0040	1.9666	10.0000	AID1873194
large T antigen	Betapolyomavirus macacae	IC50 (µMol)	20.4200	0.1600	24.9724	100.0000	AID1903
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
streptokinase A precursor	Streptococcus pyogenes M1 GAS	EC50 (µMol)	0.2695	0.0600	8.9128	130.5170	AID1902; AID1914
Albumin	Homo sapiens (human)	Kd	12.0000	0.0893	3.3135	8.0000	AID557095
Estrogen receptor	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.3620	0.0060	22.3670	130.5170	AID1914
Estrogen receptor beta	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.3620	0.0060	22.3670	130.5170	AID1914
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cellular response to starvation	Albumin	Homo sapiens (human)
negative regulation of mitochondrial depolarization	Albumin	Homo sapiens (human)
cellular response to calcium ion starvation	Albumin	Homo sapiens (human)
cellular oxidant detoxification	Albumin	Homo sapiens (human)
transport	Albumin	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
renal water homeostasis	Guanine nucleotide-binding protein G	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Guanine nucleotide-binding protein G	Homo sapiens (human)
regulation of insulin secretion	Guanine nucleotide-binding protein G	Homo sapiens (human)
cellular response to glucagon stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
lipid transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid biosynthetic process	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate metabolic process	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transmembrane transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transepithelial transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
renal urate salt excretion	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
export across plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transport across blood-brain barrier	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
cellular detoxification	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
oxygen binding	Albumin	Homo sapiens (human)
DNA binding	Albumin	Homo sapiens (human)
fatty acid binding	Albumin	Homo sapiens (human)
copper ion binding	Albumin	Homo sapiens (human)
protein binding	Albumin	Homo sapiens (human)
toxic substance binding	Albumin	Homo sapiens (human)
antioxidant activity	Albumin	Homo sapiens (human)
pyridoxal phosphate binding	Albumin	Homo sapiens (human)
identical protein binding	Albumin	Homo sapiens (human)
protein-folding chaperone binding	Albumin	Homo sapiens (human)
exogenous protein binding	Albumin	Homo sapiens (human)
enterobactin binding	Albumin	Homo sapiens (human)
G protein activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
adenylate cyclase activator activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
efflux transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP hydrolysis activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
identical protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
protein homodimerization activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular region	Albumin	Homo sapiens (human)
extracellular space	Albumin	Homo sapiens (human)
nucleus	Albumin	Homo sapiens (human)
endoplasmic reticulum	Albumin	Homo sapiens (human)
endoplasmic reticulum lumen	Albumin	Homo sapiens (human)
Golgi apparatus	Albumin	Homo sapiens (human)
platelet alpha granule lumen	Albumin	Homo sapiens (human)
extracellular exosome	Albumin	Homo sapiens (human)
blood microparticle	Albumin	Homo sapiens (human)
protein-containing complex	Albumin	Homo sapiens (human)
cytoplasm	Albumin	Homo sapiens (human)
plasma membrane	Guanine nucleotide-binding protein G	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
nucleoplasm	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
brush border membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
mitochondrial membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
membrane raft	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
external side of apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (497)

Assay ID	Title	Year	Journal	Article
AID565818	Antimicrobial activity against Neisseria gonorrhoeae isolates up to 2 ug/ml by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
AID561776	Antimicrobial activity against Staphylococcus aureus isolate 27657 expressing FusC by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID324689	Antimicrobial activity against Staphylococcus aureus CS957	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID285348	Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus HT20020488 in CCY medium	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID510748	Antibacterial activity against Escherichia coli AG102MB harboring naive acrB gene	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID285350	Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus HT20040332 in CCY media	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID323834	Antibacterial activity against fusidic acid resistant Clostridium difficile 26:3 isolate with fusA M16I and H455N mutation after 35 to 40 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID325448	Antibacterial activity against Staphylococcus aureus Mu50 after 14 to 16 hrs by broth dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Polyamine effects on antibiotic susceptibility in bacteria.
AID557093	Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID285344	Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus HT20040332 in Mueller-Hinton medium	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID424579	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH340 (SCV-12) harboring Gly617Asp mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID424613	Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH287 harboring Ala655Glu mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID561996	Antimicrobial activity against Staphylococcus aureus RN4220 transformed with Staphylococcus aureus isolate 27971 carrying pUB101 expressing cadX coding sequence by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID525129	Suppression of drug resistance development in Staphylococcus aureus RN4220 assessed as prolonged length of subculture to develop Linezolid resistance at 4 times MIC and 0.25 times IC50 after 25 days	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents.
AID424343	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH206 harboring Arg464Ser mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID519481	Antibacterial activity against Staphylococcus aureus T991 by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances.
AID283560	Antibacterial activity against Escherichia coli HNCE4 after 24 hrs	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID1904946	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 infected in BALB/c mouse assessed as reduction in bacterial count in spleen administered 72 hrs post infection topically twice daily for 4 days	2022	European journal of medicinal chemistry, Apr-15, Volume: 234	Exploring the structure-activity relationships of diphenylurea as an antibacterial scaffold active against methicillin- and vancomycin-resistant Staphylococcus aureus.
AID324711	Antimicrobial activity against Staphylococcus aureus RN4220 expressing (pAJ96:SAS0043) (fusC) gene	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID297186	Antibacterial activity against multidrug resistant Staphylococcus aureus 49589	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Structure-activity relationships of phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms.
AID584115	Antibacterial activity against Escherichia coli KAM32 harboring pSP72 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
AID424574	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH369 (SCV-41) harboring Gln115Leu mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID520086	Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring AcrAB efflux pump by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID581655	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient at pH 7.4 after 48 hrs by broth microdilution method in presence of thymidine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID1532493	Cytotoxicity against human KBV cells assessed as cell viability at 5 uM after 72 hrs by MTT assay relative to control
AID285347	Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus HT20010734 in CCY medium	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID279570	Antimicrobial activity against Salmonella enterica serovar Typhimurium JB393 in Caenorhabditis elegans	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Caenorhabditis elegans as a model to determine fitness of antibiotic-resistant Salmonella enterica serovar typhimurium.
AID545937	Ratio of MIC for Klebsiella pneumoniae ATCC 13883 to MIC for Klebsiella pneumoniae ATCC 13883 in presence of 4 ug/ml of NAB741	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID324694	Antimicrobial activity against Staphylococcus aureus CS992	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID1230066	Antibacterial activity against methicillin-resistant Staphylococcus aureus GRE2691 assessed as inhibition of bacterial growth	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis and antimicrobial activity of chloramphenicol-polyamine conjugates.
AID424594	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH349 (SCV-21) harboring -1 frameshift mutation at nucleotide 404 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID261274	Antibacterial activity against Staphylococcus aureus CJ 234 R	2006	Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5	Synthesis and biological evaluation of photoaffinity labeled fusidic acid analogues.
AID571211	Antibacterial activity against Acinetobacter baumannii F264 by Etest method in presence of NAB739	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID424581	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH329 (SCV-1) harboring Arg659Cys mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1904945	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 infected in BALB/c mouse assessed as reduction in bacterial count administered 72 hrs post infection topically twice daily for 4 days	2022	European journal of medicinal chemistry, Apr-15, Volume: 234	Exploring the structure-activity relationships of diphenylurea as an antibacterial scaffold active against methicillin- and vancomycin-resistant Staphylococcus aureus.
AID681728	TP_TRANSPORTER: inhibition of Taurocholate uptake in canalicular membrane vesicles of rat liver	2002	Biochemical pharmacology, Jul-01, Volume: 64, Issue:1	Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate.
AID261279	Antibacterial activity against Corynebacterium xerosis FF	2006	Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5	Synthesis and biological evaluation of photoaffinity labeled fusidic acid analogues.
AID424601	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH378 (SCV-50) harboring -1 frameshift mutation at nucleotide 221 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID285341	Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus HT20010734 in in Mueller-Hinton medium	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID571394	Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 0.5 ug/ml NAB739	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID561989	Antimicrobial activity against cadXD coding sequence deficient Staphylococcus aureus isolate 27856 expressing FusB by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID91481	Binding constant against human serum albumin (HSA)	2001	Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25	Cheminformatic models to predict binding affinities to human serum albumin.
AID1532501	Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID557115	Binding affinity to human serum albumin assessed as fraction of binding sites occupied by compound at 20 ug/ml by SPR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID424829	Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH420 harboring deletion of nucleotide 72-80 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID323857	Antibacterial activity against fusidic acid resistant Clostridium difficile 58:1 isolate with fusA H455Q mutation after 1 day	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID571390	Antibacterial activity against Acinetobacter baumannii F264 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID424337	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH194 harboring Pro404Leu mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID373748	Antimicrobial activity against mupirocin-resistant methicillin-resistant Staphylococcus aureus by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals.
AID586056	Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type 6 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID519833	Antimicrobial activity against Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID324697	Antimicrobial activity against Staphylococcus aureus CS866	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID1322511	Antibacterial activity against Staphylococcus aureus infected in BALB/c mouse model of superficial skin infection and biofilm formation assessed as reduction in bacterial load in skin at 40 mg/kg applied topically once daily for 4 days and measured 18 hrs
AID565817	Antimicrobial activity against Neisseria gonorrhoeae isolates by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
AID396041	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pBGS18 plasmid by standard disk diffusion method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID571393	Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 1 ug/ml NAB739	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID1532513	Antibacterial activity against Staphylococcus aureus
AID545935	Ratio of MIC for Escherichia coli ATCC 25922 to MIC for Escherichia coli ATCC 25922 in presence of 4 ug/ml of NAB741	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID261277	Antibacterial activity against Staphylococcus aureus CJ 288	2006	Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5	Synthesis and biological evaluation of photoaffinity labeled fusidic acid analogues.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID558031	Drug concentration in human plasma	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID396037	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by standard disk diffusion method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID576355	Antibacterial activity against fusidic acid-resistant, methicillin-susceptible Staphylococcus aureus after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID519482	Antibacterial activity against Staphylococcus aureus T2019 with G2576T mutation in 23S rRNA genes by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances.
AID576377	Antibacterial activity against Staphylococcus aureus harboring L461Kb and C473S mutations in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1209457	Unbound Cmax in human plasma	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID565820	Antimicrobial activity against Chlamydia trachomatis isolates	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
AID424596	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH358 (SCV-30) harboring -1 frameshift mutation at nucleotide 423 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID586046	Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type 2 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID575170	Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 200 uM by spectrofluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID576354	Antibacterial activity against fusidic acid-resistant, methicillin-resistant Staphylococcus aureus after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID323852	Antibacterial activity against fusidic acid resistant Clostridium difficile 100:2 isolate with fusA V119A mutation after 8 to 13 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID1415898	Antiplasmodial activity against Plasmodium falciparum D10 after 48 hrs	2017	MedChemComm, Jun-01, Volume: 8, Issue:6	Identification of steroid-like natural products as antiplasmodial agents by 2D and 3D similarity-based virtual screening.
AID424592	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH392 (SCV-64) harboring -1 frameshift mutation at nucleotide 383 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1382508	Toxicity in wounded skin area of Balb/c mouse infected with methicillin-resistant Staphylococcus aureus USA300 at 2% administered topically twice daily for 5 consecutive days measured 12 hrs post last dose	2018	European journal of medicinal chemistry, Mar-25, Volume: 148	Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
AID576356	Antibacterial activity against fusidic acid-resistant methicillin-resistant Staphylococcus aureus harboring P404L mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID520088	Antimicrobial activity against Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID545933	Antimicrobial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 4 ug/ml NAB741	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID285162	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as bacterial density after 10 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID324708	Antimicrobial activity against Staphylococcus aureus RN4220 expressing (pCU1:SSP2165) (fusD) gene	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID576364	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring L461K mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID565480	Antimicrobial activity against methicillin-resistant Staphylococcus aureus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro bactericidal activity of iclaprim in human plasma.
AID424582	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH331 (SCV-3) harboring Arg659His mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID581668	Antibacterial activity against revertant Staphylococcus aureus infected in human THP-1 cells assessed as log reduction of extracellular CFU level after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID323833	Antibacterial activity against fusidic acid resistant Clostridium difficile 26:2 isolate with fusA D432N mutation after 8 to 13 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID561774	Antimicrobial activity against Staphylococcus aureus isolate 27971 expressing FusB and harboring pUB101 carrying cadX coding sequence by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID424615	Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH297 harboring Ser660Pro mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID571395	Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 0.25 ug/ml NAB739	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID424825	Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH292 harboring Gly664Val mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID323850	Antibacterial activity against fusidic acid resistant Clostridium difficile 73:2 isolate with fusA I459R mutation after 8 to 13 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID424607	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH390 (SCV-62) harboring +1 frameshift mutation at nucleotide 84 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1209456	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1566017	Cytotoxicity against human KBV cells assessed as cell survival at 5 uM after 72 hrs by MTT assay relative to control	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Discovery and synthesis of 3- and 21-substituted fusidic acid derivatives as reversal agents of P-glycoprotein-mediated multidrug resistance.
AID510749	Antibacterial activity against Escherichia coli AG102MB harboring pP10-based acrB gene	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID1532503	Cytotoxicity against human KBV cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID576357	Antibacterial activity against fusidic acid-resistant methicillin-susceptible Staphylococcus aureus harboring P404L mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID324709	Antimicrobial activity against Staphylococcus aureus RN4220 expressing pAJ96	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID424832	Ratio of MIC for kanamycin-resistant Staphylococcus aureus harboring mutations in FusE gene to MIC for wild type kanamycin-susceptible Staphylococcus aureus AH001	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID561767	Antimicrobial activity against cadX coding sequence deficient Staphylococcus aureus isolate 27962 expressing FusA Met453Ile mutant and harboring pMW2 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID323838	Antibacterial activity against fusidic acid resistant Clostridium difficile 51:1 isolate after 1 day	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID404304	Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID571429	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of 1 ug/ml NAB739	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID424589	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH370 (SCV-42) harboring TAA stop codon at nucleotide 229 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID581666	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU level after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID396040	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP3 plasmid containing Enterobacter aerogenes acrR gene by standard disk diffusion method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID586053	Antimicrobial activity against Staphylococcus aureus clone 4-4 harboring staphylococcal cassette chromosome mec element type 4 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID424580	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH332 (SCV-4) harboring Ala655Glu mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID285349	Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus HT20030203 in CCY media	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID565484	Bactericidal activity against methicillin-resistant Staphylococcus aureus after 24 hrs by M26-A method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro bactericidal activity of iclaprim in human plasma.
AID576371	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring A71V in domain 1 and P404L mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID581658	Cmax in human plasma	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID581664	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level per mg of protein after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID285340	Antibacterial activity against Staphylococcus aureus LUG855 in Mueller-Hinton medium	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID557094	Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 1.6% gamma globulin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID557117	Binding affinity to human serum albumin assessed as fraction of binding sites occupied by compound at 215 to 430 ug/ml by SPR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID561764	Antimicrobial activity against Staphylococcus aureus isolate 27731 expressing FusA Ala71Val, Asp189Gly, Pro406Leu mutant and harboring pMW2 carrying cadX coding sequence by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID1575939	Antimycobacterial activity against Mycobacterium tuberculosis H37RvMA ATCC 27294 cultured in protein-based Middlebrook 7H9 medium supplemented with glucose, albumin-dextrose-catalase and Tween 80 assessed as inhibition of bacterial growth incubated for 7
AID1720195	Cytotoxicity against CHOK1 cells assessed as reduction in cell viability	2020	Bioorganic & medicinal chemistry, 07-01, Volume: 28, Issue:13	Structure-activity relationship analyses of fusidic acid derivatives highlight crucial role of the C-21 carboxylic acid moiety to its anti-mycobacterial activity.
AID323849	Antibacterial activity against fusidic acid resistant Clostridium difficile 73:1 isolate after 1 day	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID558037	Cytotoxicity against human SVG-A cells	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID525127	Suppression of drug resistance development in recA-deficient Staphylococcus aureus KB103 assessed as prolonged length of subculture to develop Linezolid resistance at 4 times MIC and 0.25 times IC50 after 20 days	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents.
AID565813	Antimicrobial activity against Neisseria gonorrhoeae assessed as susceptible isolates by CLSI method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
AID285161	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as relative light unit after 11 days by LORA assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID285351	Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus HT20041010 in CCY media	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID424597	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH339 (SCV-11) harboring -1 frameshift mutation at nucleotide 144 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID576359	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring E444K mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID324717	Antimicrobial activity against Staphylococcus lugdunensis 16496	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID424590	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH346 (SCV-18) harboring -1 frameshift mutation at nucleotide 238 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID324690	Antimicrobial activity against Staphylococcus aureus	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID581665	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU level at up to 10'5 times MIC after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID565502	Plasma protein binding in human	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro bactericidal activity of iclaprim in human plasma.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID324707	Antimicrobial activity against Staphylococcus aureus RN4220 expressing (pCU1:SAS0043) (fusC) gene	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID561990	Antimicrobial activity against cadXD coding sequence deficient Staphylococcus aureus isolate 27971 expressing FusB by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID1361132	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 in BALB/c mouse wound infection model assessed as reduction in bacterial burden in wound at 2% administered topically bid for 5 days relative to control	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	N-(1,3,4-oxadiazol-2-yl)benzamide analogs, bacteriostatic agents against methicillin- and vancomycin-resistant bacteria.
AID424600	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH384 (SCV-56) harboring -1 frameshift mutation at nucleotide 221 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID565814	Antimicrobial activity against Neisseria gonorrhoeae assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
AID1532492	Cytotoxicity against human HeLa cells assessed as cell viability at 1.5 uM after 72 hrs by MTT assay relative to control
AID561992	Antimicrobial activity against Staphylococcus aureus RN4220 transformed with Staphylococcus aureus isolate 28332 carrying pUB101 cadX coding sequence by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID571213	Antibacterial activity against Acinetobacter baumannii F264 by Etest method in presence of 0.5 ug/ml NAB739	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID679021	TP_TRANSPORTER: inhibition of LTC4 uptake in Mrp2-expressing HEK cells	2002	Biochemical pharmacology, Jul-01, Volume: 64, Issue:1	Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate.
AID285343	Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus HT20030203 in Mueller-Hinton medium	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID520085	Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring plasmid pEX19Gm by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID576369	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring A67T in domain 1 and H457Y mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID325443	Antibacterial activity against Escherichia coli K10 after 14 to 16 hrs by broth dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Polyamine effects on antibiotic susceptibility in bacteria.
AID1460343	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 by [3H]hypoxanthine incorporation assay	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Synthesis and biological characterisation of ester and amide derivatives of fusidic acid as antiplasmodial agents.
AID561985	Antimicrobial activity against Staphylococcus aureus isolate 28084 expressing FusC and harboring pMW2 carrying cadX coding sequence by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID540930	Antimicrobial activity against paromomycin-resistant Streptomyces coelicolor 92G harboring rpsL gene with inserted glycine at position 92 after 48 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID525124	Suppression of resistance related recombination in Staphylococcus aureus RN4220 at 0.25 times MIC at 42 degC	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents.
AID561982	Antimicrobial activity against cadX coding sequence deficient Staphylococcus aureus isolate 28400 expressing FusC C90T mutant and harboring pMW2 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID1482267	Antibacterial activity against Escherichia coli MG1655 measured every 15 mins for 12 hrs	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure.
AID540931	Antimicrobial activity against paromomycin-resistant Streptomyces coelicolor SP1 harboring rpsL A262G and C271T mutant gene after 48 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID324696	Antimicrobial activity against Staphylococcus aureus CS808	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID355207	Cytotoxicity against african green monkey Vero cells after 72 hrs	1996	Journal of natural products, Dec, Volume: 59, Issue:12	Antimycobacterial cycloartanes from Borrichia frutescens.
AID561995	Antimicrobial activity against Staphylococcus aureus RN4220 transformed with Staphylococcus aureus isolate 27856 carrying pUB101 expressing cadX coding sequence by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID1532505	Induction of apoptosis in human HeLa cells assessed as increase in early apoptotic cells at 2 uM after 24 hrs by TUNEL staining based fluorescence microscopic analysis
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID424611	Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH288 harboring Gly617Asp mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID424583	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH347 (SCV-19) harboring Arg659Ser mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID424344	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH190 harboring Arg464His mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1532494	Cytotoxicity against human KBV cells assessed as cell viability at 1.5 uM after 72 hrs by MTT assay relative to control
AID424573	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH366 (SCV-38) harboring Pro114His mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID576112	Antimicrobial activity against mecA-positive Staphylococcus sciuri harboring staphylococcus aureus mecA gene assessed as resistant isolates	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Nasal carriage of methicillin-resistant and methicillin-sensitive strains of Staphylococcus sciuri in the Indonesian population.
AID1415896	Cytotoxicity against CHO cells by MTT assay	2017	MedChemComm, Jun-01, Volume: 8, Issue:6	Identification of steroid-like natural products as antiplasmodial agents by 2D and 3D similarity-based virtual screening.
AID565481	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro bactericidal activity of iclaprim in human plasma.
AID424584	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH367 (SCV-39) harboring Gly664Ser mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID424341	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH197 harboring Leu456Phe mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID324712	Antimicrobial activity against Staphylococcus aureus RN4220 expressing (pAJ96:SSP2165) (fusD) gene	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID323856	Antibacterial activity against fusidic acid resistant Clostridium difficile 248:3 isolate with fusA H455R mutation after 35 to 40 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID324695	Antimicrobial activity against Staphylococcus aureus CS730	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID1594381	Induction of inflammation in wounded skin area of Balb/c mouse infected with methicillin-resistant Staphylococcus aureus USA300 at 2% administered topically twice daily for 5 consecutive days measured 4 times daily during compound dosing	2019	Bioorganic & medicinal chemistry, 05-01, Volume: 27, Issue:9	Second-generation aryl isonitrile compounds targeting multidrug-resistant Staphylococcus aureus.
AID323835	Antibacterial activity against fusidic acid resistant Clostridium difficile 49:1 isolate after 1 day	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID324716	Antimicrobial activity against Staphylococcus lugdunensis 16641	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID324714	Antimicrobial activity against Staphylococcus intermedius CL2	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID324704	Antimicrobial activity against Staphylococcus aureus CS860	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID585877	Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type 4 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID557090	Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 0.1% alpha-1-acid glycoprotein	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID586052	Antimicrobial activity against Staphylococcus aureus clone 4-4 harboring staphylococcal cassette chromosome mec element type 2 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID540927	Antimicrobial activity against Streptomyces coelicolor 1147 after 48 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID520081	Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID396034	Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump by standard disk diffusion method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID561980	Antimicrobial activity against cadX coding sequence deficient Staphylococcus aureus isolate 28150 expressing FusC and harboring pMW2 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID576360	Antibacterial activity against Staphylococcus aureus harboring G451V mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID424577	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH336 (SCV-8) harboring His438Asn mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID586038	Antimicrobial activity against Staphylococcus aureus clone 1-1 harboring staphylococcal cassette chromosome mec element type U assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID324715	Antimicrobial activity against Staphylococcus intermedius NCTC 11048	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID576363	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring H457Y mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID424345	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH188 harboring Gly664Ser mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID586051	Antimicrobial activity against Staphylococcus aureus clone 4-4 harboring staphylococcal cassette chromosome mec element type 1 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID325444	Antibacterial activity against Escherichia coli K12 after 14 to 16 hrs by broth dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Polyamine effects on antibiotic susceptibility in bacteria.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID576374	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring E444V and L461F mutations in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID424340	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH201 harboring Gly452Cys mutation in fusA after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID584114	Antibacterial activity against Escherichia coli KAM32 harboring Staphylococcus aureus cloned pSP72 lmrS by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
AID565819	Trough plasma concentration in human	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
AID424567	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH204 harboring deletion of nucleotide 203-231 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID586041	Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type 5 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID561768	Antimicrobial activity against Staphylococcus aureus isolate 28362 expressing FusA Val90Ile mutant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID424595	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH374 (SCV-46) harboring -5 frameshift mutation at nucleotide 236-240 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID323846	Antibacterial activity against fusidic acid resistant Clostridium difficile 63:2 isolate with fusA T434I after 8 to 13 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID224494	In vitro inhibition of protein synthesis in tobacco mosaic virus mRNA-encoded proteins in rabbit reticulocyte lysate	2000	Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22	Inhibition of protein synthesis by didemnins: cell potency and SAR.
AID540928	Antimicrobial activity against streptomycin-resistant Streptomyces coelicolor KO-178 harboring rpsL K88E mutant gene after 48 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID424576	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH334 (SCV-6) harboring Thr436Ile mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1382507	Induction of inflammation in Balb/c mouse infected with methicillin-resistant Staphylococcus aureus USA300 assessed as swelling around wounded skin area at 2% administered topically twice daily for 5 consecutive days measured 12 hrs post last dose	2018	European journal of medicinal chemistry, Mar-25, Volume: 148	Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
AID323844	Antibacterial activity against fusidic acid resistant Clostridium difficile 62:3 isolate with fusA A375 deletion after 35 to 40 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID323848	Antibacterial activity against fusidic acid resistant Clostridium difficile 72:2 isolate with fusA S116L and A374V mutation after 8 to 13 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID1532504	Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID540929	Antimicrobial activity against paromomycin-resistant Streptomyces coelicolor KO-347 harboring rpsl P91S mutant gene after 48 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID424608	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH386 (SCV-58) harboring -1 frameshift mutation at nucleotide 90 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID323839	Antibacterial activity against fusidic acid resistant Clostridium difficile 51:2 isolate with fusA S449P mutation after 8 to 13 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID424342	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH187 harboring His457Tyr mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID586055	Antimicrobial activity against Staphylococcus aureus clone 4-4 harboring staphylococcal cassette chromosome mec element type U3 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID1873194	Inhibition of ABCG2 (unknown origin) expressed in dog MDCK-II-BCRP cells incubated for 120 mins by transwell migration assay	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID571209	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of 0.125 ug/ml NAB739	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID323836	Antibacterial activity against fusidic acid resistant Clostridium difficile 49:2 isolate after 8 to 13 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID424824	Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH296 harboring Gly664Ala mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID571212	Antibacterial activity against Acinetobacter baumannii F264 by Etest method in presence of 1 ug/ml NAB739	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID565485	Bactericidal activity against methicillin-susceptible Staphylococcus aureus after 24 hrs by M26-A method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro bactericidal activity of iclaprim in human plasma.
AID586054	Antimicrobial activity against Staphylococcus aureus clone 4-4 harboring staphylococcal cassette chromosome mec element type 5 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID1532496	Cytotoxicity against human U87 cells assessed as cell viability at 1.5 uM after 72 hrs by MTT assay relative to control
AID557097	Protein binding in serum	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID323854	Antibacterial activity against fusidic acid resistant Clostridium difficile 107:3 isolate with fusA A459R mutation after 35 to 40 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID1904944	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 infected in BALB/c mouse assessed as recovery of body weight loss administered 72 hrs post infection topically twice daily for 4 days	2022	European journal of medicinal chemistry, Apr-15, Volume: 234	Exploring the structure-activity relationships of diphenylurea as an antibacterial scaffold active against methicillin- and vancomycin-resistant Staphylococcus aureus.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID565491	Ratio of MBC to MIC for methicillin-susceptible Staphylococcus aureus in presence of 50% human plasma	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro bactericidal activity of iclaprim in human plasma.
AID325449	Antibacterial activity against Staphylococcus aureus ATCC 3556 after 14 to 16 hrs by broth dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Polyamine effects on antibiotic susceptibility in bacteria.
AID324699	Antimicrobial activity against Staphylococcus aureus CS851	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID325446	Antibacterial activity against Salmonella enterica serovar Typhimurium LT2 after 14 to 16 hrs by broth dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Polyamine effects on antibiotic susceptibility in bacteria.
AID424568	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH209 harboring deletion of nucleotide 404-427 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID561777	Antimicrobial activity against Staphylococcus aureus isolate 28416 expressing FusC by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID424614	Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH291 harboring Arg659His mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID584117	Antibacterial activity against Escherichia coli KAM32 harboring Staphylococcus aureus cloned pSP72 lmrS by broth microdilution method in presence of efflux pump inhibitor CCCP	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
AID576367	Antibacterial activity against methicillin-susceptible Staphylococcus aureus harboring M651I mutation in domain 5 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID396039	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pACYC184 plasmid by standard disk diffusion method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID324693	Antimicrobial activity against Staphylococcus aureus RN4220 expressing pCU1:fusB gene	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID1428626	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 by broth microdilution method	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.
AID576111	Antimicrobial activity against mecA-deficient Staphylococcus sciuri harboring staphylococcus aureus mecA gene assessed as resistant isolates	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Nasal carriage of methicillin-resistant and methicillin-sensitive strains of Staphylococcus sciuri in the Indonesian population.
AID581671	Antibacterial activity against normal phenotype Staphylococcus aureus in cation-adjusted MH 2 broth at pH 5.5 after 24 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID581670	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth at pH 5.5 after 48 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID477409	Antibacterial activity against Staphylococcus aureus NCTC 8325 after 16 to 20 hrs by broth microdilution method	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR.
AID1575940	Antimycobacterial activity against Mycobacterium tuberculosis H37RvMA ATCC 27294 cultured in non protein-based Middlebrook 7H9 medium supplemented with glucose-casitone-tyloxapol assessed as inhibition of bacterial growth incubated for 7 days in by alamar
AID323845	Antibacterial activity against fusidic acid resistant Clostridium difficile 63:1 isolate after 1 day	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID1575942	Antimycobacterial activity against Mycobacterium tuberculosis
AID355206	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 3 days by radiorespirometric assay	1996	Journal of natural products, Dec, Volume: 59, Issue:12	Antimycobacterial cycloartanes from Borrichia frutescens.
AID424348	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH202 harboring CTG start codon at nucleotide 1 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID575169	Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 1000 uM by spectrofluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID424602	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH351 (SCV-23) harboring -4 frameshift mutation at nucleotide 45-48 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID561988	Antimicrobial activity against cadXD coding sequence deficient Staphylococcus aureus isolate 27624 expressing FusB by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID424598	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH337 (SCV-9) harboring -1 frameshift mutation at nucleotide 220 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID586049	Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type U6 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID1460342	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 by LDH assay	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Synthesis and biological characterisation of ester and amide derivatives of fusidic acid as antiplasmodial agents.
AID545917	Antimicrobial activity against Escherichia coli ATCC 25922 by Etest method in presence of 4 ug/ml NAB741	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID679028	TP_TRANSPORTER: inhibition of E217betaG uptake in canalicular membrane vesicles of rat liver	2002	Biochemical pharmacology, Jul-01, Volume: 64, Issue:1	Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate.
AID424833	Ratio of MIC for kanamycin-resistant Staphylococcus aureus harboring mutations in FusA gene to MIC for wild type kanamycin-susceptible Staphylococcus aureus AH001	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID324719	Antimicrobial activity against Staphylococcus lugdunensis 40869	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID557096	Binding affinity to human alpha-1-acid glycoprotein assessed as compound binding sites level by SPR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID525128	Suppression of drug resistance development in Staphylococcus aureus isolate EMRAS-15 assessed as prolonged length of subculture to develop Linezolid resistance at 4 times MIC and 0.25 times IC50 after 25 days	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents.
AID557116	Binding affinity to human serum albumin assessed as fraction of binding sites occupied by compound at 160 ug/ml by SPR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID424587	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH377 (SCV-49) harboring +1 frameshift mutation at nucleotide 23 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID576375	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring H457Q and L461F mutations in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID571428	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of 0.5 ug/ml NAB739	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID519834	Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID561993	Antimicrobial activity against Staphylococcus aureus RN4220 transformed with Staphylococcus aureus isolate 28444 carrying pUB101 expressing cadX coding sequence by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID679020	TP_TRANSPORTER: inhibition of LTC4 uptake in canalicular membrane vesicles of rat liver	2002	Biochemical pharmacology, Jul-01, Volume: 64, Issue:1	Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate.
AID1266403	Competitive inhibition of chloramphenicol acetyl transferase (unknown origin) assessed as binding affinity	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	New Frontiers in Druggability.
AID285160	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed as bacterial density after 7 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID557092	Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 50% human serum	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID323847	Antibacterial activity against fusidic acid resistant Clostridium difficile 72:1 isolate after 1 day	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID323843	Antibacterial activity against fusidic acid resistant Clostridium difficile 62:2 isolate after 8 to 13 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID261273	Antibacterial activity against Staphylococcus aureus CJ 247	2006	Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5	Synthesis and biological evaluation of photoaffinity labeled fusidic acid analogues.
AID576361	Antibacterial activity against Staphylococcus aureus harboring M453I mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID557095	Binding affinity to first site on human serum albumin by SPR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID324698	Antimicrobial activity against Staphylococcus aureus CS602	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID424609	Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible wild type Staphylococcus aureus 8325-4 clinical isolate after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID510750	Antibacterial activity against Escherichia coli AG102MB harboring pS1328-based acrB gene	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID323842	Antibacterial activity against fusidic acid resistant Clostridium difficile 62:1 isolate after 1 day	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID1443980	Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch	2010	Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID565490	Ratio of MBC to MIC for methicillin-resistant Staphylococcus aureus in presence of 50% human plasma	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro bactericidal activity of iclaprim in human plasma.
AID1460341	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 infected in erythrocytes after 48 hrs by giemsa staining based assay	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Synthesis and biological characterisation of ester and amide derivatives of fusidic acid as antiplasmodial agents.
AID324703	Antimicrobial activity against Staphylococcus aureus CS805	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID324713	Antimicrobial activity against Staphylococcus intermedius CL1	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID324700	Antimicrobial activity against Staphylococcus aureus CS979	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID1209455	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1532500	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID424606	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH330 (SCV-2) harboring -1 frameshift mutation at nucleotide 423 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID424612	Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH294 harboring Gly628Val mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID424828	Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH290 harboring duplication mutation at nucleotide 202-293 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID424586	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH352 (SCV-24) harboring -1 frameshift mutation at nucleotide 106 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID571397	Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID561987	Antimicrobial activity against cadXD coding sequence deficient Staphylococcus aureus isolate 28444 expressing FusB by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID1382502	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 in Balb/c mouse skin infection model assessed as reduction in bacterial burden in wounded skin area at 2% administered topically twice daily for 5 consecutive days measured	2018	European journal of medicinal chemistry, Mar-25, Volume: 148	Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
AID424346	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH193 harboring TAA stop codon at nucleotide 299 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID497969	Antimicrobial activity against Staphylococcus aureus SJ11617	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Continuous clindamycin infusion, an innovative approach to treating bone and joint infections.
AID571208	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of 0.25 ug/ml NAB739	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID561772	Antimicrobial activity against Staphylococcus aureus isolate 27624 expressing FusB and harboring pUB101 carrying cadX coding sequence by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID586047	Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type 6 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID576358	Antibacterial activity against Staphylococcus aureus harboring P406L mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID585879	Antimicrobial activity against Staphylococcus aureus clone 1-1 harboring staphylococcal cassette chromosome mec element type 5 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID520082	Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring AheABC efflux pump by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID576370	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring A70V in domain 1 and H457Y mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID1382506	Induction of inflammation in Balb/c mouse infected with methicillin-resistant Staphylococcus aureus USA300 assessed as redness around wounded skin area at 2% administered topically twice daily for 5 consecutive days measured 12 hrs post last dose relative	2018	European journal of medicinal chemistry, Mar-25, Volume: 148	Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
AID576110	Antimicrobial activity against mecA-positive Staphylococcus sciuri assessed as resistant isolates	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Nasal carriage of methicillin-resistant and methicillin-sensitive strains of Staphylococcus sciuri in the Indonesian population.
AID424336	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH207 harboring Thr385Asn mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID576109	Antimicrobial activity against mecA-deficient Staphylococcus sciuri assessed as resistant isolates	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Nasal carriage of methicillin-resistant and methicillin-sensitive strains of Staphylococcus sciuri in the Indonesian population.
AID424591	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH333 (SCV-5) harboring TAA stop codon at nucleotide 249 in rplF but gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID424578	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH338 (SCV-10) harboring Arg464Cys mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID325445	Antibacterial activity against Escherichia coli C921-61 after 14 to 16 hrs by broth dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Polyamine effects on antibiotic susceptibility in bacteria.
AID545929	Antimicrobial activity against Enterobacter cloacae ATCC 23355 by Etest method in presence of 4 ug/ml NAB741	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID1594380	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 infected in Balb/c mouse assessed as reduction in bacterial burden in wounded skin area at 2% administered topically twice daily for 5 consecutive days measured 12 hrs post	2019	Bioorganic & medicinal chemistry, 05-01, Volume: 27, Issue:9	Second-generation aryl isonitrile compounds targeting multidrug-resistant Staphylococcus aureus.
AID1460345	Selectivity index, ratio of IC50 for CHO cells to IC50 for chloroquine-sensitive Plasmodium falciparum NF54	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Synthesis and biological characterisation of ester and amide derivatives of fusidic acid as antiplasmodial agents.
AID424610	Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH421 harboring Pro404Arg mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID510747	Antibacterial activity against Escherichia coli AG102MB harboring pSport1-based acrB gene	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID424826	Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH298 harboring Gly664Val mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID520083	Antimicrobial activity against aheB-deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring AheABC efflux pump by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID424827	Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH422 harboring +2 frameshift mutation at nucleotide 222 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID323858	Antibacterial activity against fusidic acid resistant Clostridium difficile 58:2 isolate with fusA H455Q mutation after 8 to 13 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID576376	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring H457Q and L461K mutations in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID545925	Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 by Etest method in presence of 4 ug/ml NAB741	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID1532498	Cytotoxicity against human MKN45 cells assessed as cell viability at 1.5 uM after 72 hrs by MTT assay relative to control
AID565483	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus by broth microdilution method in presence of 50% human plasma	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro bactericidal activity of iclaprim in human plasma.
AID565816	Antimicrobial activity against Neisseria gonorrhoeae assessed as resistant isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID323841	Antibacterial activity against fusidic acid resistant Clostridium difficile 57:3 isolate with fusA S116L and A374V mutation after 35 to 40 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID424599	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH357 (SCV-29) harboring TAA stop codon at nucleotide 301 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID561769	Antimicrobial activity against Staphylococcus aureus isolate 28130 expressing FusA Leu461Ser mutant pMW2 carrying cadX coding sequence by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID581653	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU after 5 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID283559	Antibacterial activity against Escherichia coli AG102MB after 24 hrs	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID561770	Antimicrobial activity against Staphylococcus aureus isolate 28332 expressing FusB and harboring pUB101 carrying cadX coding sequence by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID373750	Antimicrobial activity against mupirocin-resistant methicillin-resistant Staphylococcus aureus assessed as resistant rate by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals.
AID571396	Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 0.125 ug/ml NAB739	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID520087	Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring AheABC efflux pump by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID323853	Antibacterial activity against fusidic acid resistant Clostridium difficile 107:1 isolate after 1 day	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID373747	Antimicrobial activity against mupirocin-susceptible methicillin-resistant Staphylococcus aureus by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals.
AID392208	Antibacterial activity against Staphylococcus aureus ATCC 29213	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ.
AID323832	Antibacterial activity against fusidic acid resistant Clostridium difficile 26:1 isolate after 1 day	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID424831	Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH416 harboring deletion of nucleotide 395-398 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID571389	Antibacterial activity against Acinetobacter baumannii F264 by Etest method in presence of 0.25 ug/ml NAB739	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID571391	Antibacterial activity against Acinetobacter baumannii F264 by Etest method in presence of 0.125 ug/ml NAB739	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID561773	Antimicrobial activity against Staphylococcus aureus isolate 27856 expressing FusB and harboring pUB101 carrying cadX coding sequence by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID581669	Antibacterial activity against normal phenotype Staphylococcus aureus in infected in human THP-1 cells assessed as log reduction of extracellular CFU level after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID324701	Antimicrobial activity against Staphylococcus aureus CS1083	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID586050	Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type U8 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID545921	Antimicrobial activity against Escherichia coli IH3080 by Etest method in presence of 4 ug/ml NAB741	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID561765	Antimicrobial activity against Staphylococcus aureus isolate 27844 expressing FusA Ala376Val, Leu461Phe, Asp463Gly, Ala655Pro mutant and harboring pMW2 carrying cadX coding sequence by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID1575943	Protein binding in human serum
AID424603	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH360 (SCV-32) harboring ATA start codon at nucleotide 3 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID561983	Antimicrobial activity against cadX coding sequence deficient Staphylococcus aureus isolate 28410 expressing FusC C90T mutant and harboring pMW2 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID585878	Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type 2 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID324702	Antimicrobial activity against Staphylococcus aureus CS1128	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID586043	Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type U5 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID285342	Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus HT20020488 in Mueller-Hinton medium	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID558030	Drug concentration in human brain	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID373749	Antimicrobial activity against mupirocin-susceptible methicillin-resistant Staphylococcus aureus assessed as resistant rate by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals.
AID396038	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP2 plasmid containing Enterobacter cloacae acrA gene by standard disk diffusion method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID584116	Ratio of MIC for Escherichia coli KAM32 harboring cloned pSP72 lmrS to MIC for Escherichia coli KAM32 harboring pSP72	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
AID323855	Antibacterial activity against fusidic acid resistant Clostridium difficile 248:1 isolate after 1 day	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID424605	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH362 (SCV-34) harboring TAA stop codon at nucleotide 282 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID576373	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring A376V in domain 2 and L456F mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID261276	Antibacterial activity against Staphylococcus aureus CJ 251	2006	Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5	Synthesis and biological evaluation of photoaffinity labeled fusidic acid analogues.
AID424572	Antibacterial activity against kanamycin-susceptible wild type Staphylococcus aureus AH001 after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID324718	Antimicrobial activity against Staphylococcus lugdunensis 31440	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID424335	Antibacterial activity against fusidic acid-susceptible wild type Staphylococcus aureus 8325-4 after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID576368	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring M16I in domain 1 and H457Y mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID324705	Antimicrobial activity against Staphylococcus aureus CS1076	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID565488	Ratio of MBC to MIC for methicillin-resistant Staphylococcus aureus	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro bactericidal activity of iclaprim in human plasma.
AID561775	Antimicrobial activity against Staphylococcus aureus isolate 27980 expressing FusB and harboring pUB101 carrying cadX coding sequence by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID586039	Antimicrobial activity against Staphylococcus aureus clone 1-1 harboring staphylococcal cassette chromosome mec element type 4 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID1720196	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv	2020	Bioorganic & medicinal chemistry, 07-01, Volume: 28, Issue:13	Structure-activity relationship analyses of fusidic acid derivatives highlight crucial role of the C-21 carboxylic acid moiety to its anti-mycobacterial activity.
AID561766	Antimicrobial activity against cadX coding sequence deficient Staphylococcus aureus isolate 27768 expressing FusA Leu461Ser mutant and harboring pMW2 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID1532495	Cytotoxicity against human U87 cells assessed as cell viability at 5 uM after 72 hrs by MTT assay relative to control
AID565489	Ratio of MBC to MIC for methicillin-susceptible Staphylococcus aureus	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro bactericidal activity of iclaprim in human plasma.
AID324691	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 476	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID561986	Antimicrobial activity against cadXD coding sequence deficient Staphylococcus aureus isolate 28332 expressing FusB by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID561771	Antimicrobial activity against Staphylococcus aureus isolate 28444 expressing FusB and harboring pUB101 carrying cadX coding sequence by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID581667	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level after 24 hrs in presence of thymidine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID285159	Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID510559	Antibacterial activity against Escherichia coli AG102MB	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID396036	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate by standard disk diffusion method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID424585	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH380 (SCV-52) harboring -1 frameshift mutation at nucleotide 158 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1532497	Cytotoxicity against human MKN45 cells assessed as cell viability at 5 uM after 72 hrs by MTT assay relative to control
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID581654	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient at pH 7.4 after 48 hrs by broth microdilution method in absence of thymidine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID285346	Antibacterial activity against Staphylococcus aureus LUG855 in CCY media	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID396035	Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by standard disk diffusion method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID1289278	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 1 B690208 after 24 hrs	2016	Journal of natural products, Jan-22, Volume: 79, Issue:1	Cylindrofridins A-C, Linear Cylindrocyclophane-Related Alkylresorcinols from the Cyanobacterium Cylindrospermum stagnale.
AID581663	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level per mg of protein at up to 10'5 times MIC after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID424575	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH364 (SCV-36) harboring Asp434Asn mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID576366	Antibacterial activity against methicillin-susceptible Staphylococcus aureus harboring P478S mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID561991	Antimicrobial activity against cadXD coding sequence deficient Staphylococcus aureus isolate 27980 expressing FusB by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID1594382	Toxicity in wounded skin area of Balb/c mouse infected with methicillin-resistant Staphylococcus aureus USA300 at 2% administered topically twice daily for 5 consecutive days measured 4 times daily during compound dosing	2019	Bioorganic & medicinal chemistry, 05-01, Volume: 27, Issue:9	Second-generation aryl isonitrile compounds targeting multidrug-resistant Staphylococcus aureus.
AID323851	Antibacterial activity against fusidic acid resistant Clostridium difficile 100:1 isolate after 1 day	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID565815	Antimicrobial activity against Neisseria gonorrhoeae assessed as resistant isolates by CLSI method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
AID540932	Antimicrobial activity against paromomycin-resistant Streptomyces coelicolor SP2 harboring rpsL K88E mutant gene and inserted glycine at position 92 of the gene after 48 hrs	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID586048	Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type U1 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID323837	Antibacterial activity against fusidic acid resistant Clostridium difficile 49:3 isolate with fusA S116L and A374V mutation after 35 to 40 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID1566016	Reversal of P-gp-mediated multidrug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring cell survival at 5 uM after 72 hrs by MTT assay (Rvb = 100.58 +/- 7.78%)	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Discovery and synthesis of 3- and 21-substituted fusidic acid derivatives as reversal agents of P-glycoprotein-mediated multidrug resistance.
AID625294	Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1532506	Induction of apoptosis in human HeLa cells assessed as increase in ratio of sub-G0 to G1 phase at 5 uM after 48 to 72 hrs by propidium iodide staining based FACS analysis
AID520084	Antimicrobial activity against Escherichia coli TG1 harboring plasmid pEX19Gm by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID576362	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring H457Q mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID324710	Antimicrobial activity against Staphylococcus aureus RN4220 expressing pAJ96:fusB	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID581656	Antibacterial activity against revertant Staphylococcus aureus at pH 7.4 after 24 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID1415895	Antimalarial activity against Plasmodium falciparum NF54 infected in human erythrocytes assessed as reduction in [3H]hypoxanthine incorporation preincubated for 48 hrs followed by [3H]hypoxanthine addition measured after 24 hrs by liquid scintillation cou	2017	MedChemComm, Jun-01, Volume: 8, Issue:6	Identification of steroid-like natural products as antiplasmodial agents by 2D and 3D similarity-based virtual screening.
AID576372	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring R76C in domain 1 and H457Y mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID1887604	Antibacterial activity against Staphylococcus aureus ATCC 29213 infected in Swiss mouse skin infection model assessed as reduction in skin bacterial load at 2 % dose administered twice daily for 4 days	2022	Journal of natural products, 10-28, Volume: 85, Issue:10	Developing the Natural Prenylflavone Artocarpin from
AID324720	Antimicrobial activity against Staphylococcus saprophyticus ATCC 15305	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID1474152	AUC in patient with osteomyelitis at 1500 mg, po QD after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID324692	Antimicrobial activity against Staphylococcus aureus 649 expressing pUB101	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID1532491	Cytotoxicity against human HeLa cells assessed as cell viability at 5 uM after 72 hrs by MTT assay relative to control
AID586040	Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type 1 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID424347	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH199 harboring TAA stop codon at nucleotide 241 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID424830	Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH417 harboring -1 frameshift mutation at nucleotide 422 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID561994	Antimicrobial activity against Staphylococcus aureus RN4220 transformed with Staphylococcus aureus isolate 27624 carrying pUB101 expressing cadX coding sequence by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID1532508	Inhibition of protein synthesis in human HeLa cells assessed as decrease in puromycin-incorporated neo-synthesized proteins at 5 uM preincubated for 2 hrs followed by puromycin addition and measured after 10 mins by chemiluminescence assay
AID581659	Fraction unbound in human plasma	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID571430	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of 2 ug/ml NAB739	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID1460344	Cytotoxicity against CHO cells	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Synthesis and biological characterisation of ester and amide derivatives of fusidic acid as antiplasmodial agents.
AID424593	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH379 (SCV-51) harboring TAA stop codon at nucleotide 418 in rplF but gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID561981	Antimicrobial activity against cadX coding sequence deficient Staphylococcus aureus isolate 28335 expressing FusC C90T mutant and harboring pMW2 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID283558	Antibacterial activity against Escherichia coli AG102 with marR1 mutation after 24 hrs	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID1322509	Antibacterial activity against Staphylococcus aureus infected in BALB/c mouse model of superficial skin infection and biofilm formation assessed as reduction in bacterial load in skin at 40 mg/kg applied topically once daily for 4 days and measured 18 hrs
AID545939	Ratio of MIC for Acinetobacter baumannii ATCC 19606 to MIC for Acinetobacter baumannii ATCC 19606 in presence of 4 ug/ml of NAB741	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID558036	Therapeutic index, ratio of TC50 for JC polyomavirus M1/SVEdelta infected human SVG-A cells to EC50 for JC polyomavirus M1/SVEdelta	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID1474154	Ratio of drug concentration at steady state in patient with osteomyelitis at 1500 mg, po QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID557091	Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 4% human serum albumin	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID558029	Antiviral activity against JC polyomavirus M1/SVEdelta infected in human SVG-A cells assessed as inhibition of viral replication after 3 days	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID1532499	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID261275	Antibacterial activity against Staphylococcus aureus CJ 200	2006	Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5	Synthesis and biological evaluation of photoaffinity labeled fusidic acid analogues.
AID545936	Ratio of MIC for Escherichia coli IH3080 to MIC for Escherichia coli IH3080 in presence of 4 ug/ml of NAB741	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID586045	Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type 1 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID1532502	Cytotoxicity against human JHH7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID1230064	Antibacterial activity against methicillin-resistant Staphylococcus aureus GRE2272 assessed as inhibition of bacterial growth	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis and antimicrobial activity of chloramphenicol-polyamine conjugates.
AID561997	Antimicrobial activity against Staphylococcus aureus RN4220 transformed with Staphylococcus aureus isolate 27980 carrying pUB101 expressing cadX coding sequence by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID571210	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID571392	Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of NAB739	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID325447	Antibacterial activity against Staphylococcus aureus N315 after 14 to 16 hrs by broth dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Polyamine effects on antibiotic susceptibility in bacteria.
AID323840	Antibacterial activity against fusidic acid resistant Clostridium difficile 57:1 isolate after 1 day	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID561984	Antimicrobial activity against cadX coding sequence deficient Staphylococcus aureus isolate 28414 expressing FusC C90T mutant and harboring pMW2 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID324688	Antimicrobial activity against Staphylococcus aureus RN4220	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID545938	Ratio of MIC for Enterobacter cloacae ATCC 23355 to MIC for Enterobacter cloacae ATCC 23355 in presence of 4 ug/ml of NAB741	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID424338	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH196 harboring Pro406Leu mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID565482	Antimicrobial activity against methicillin-resistant Staphylococcus aureus by broth microdilution method in presence of 50% human plasma	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro bactericidal activity of iclaprim in human plasma.
AID1230065	Antibacterial activity against methicillin-resistant Staphylococcus aureus GRE2372 assessed as inhibition of bacterial growth	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis and antimicrobial activity of chloramphenicol-polyamine conjugates.
AID1474153	Drug concentration at steady state in patient with osteomyelitis at 1500 mg, po QD after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID424339	Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH198 harboring Gly452Ser mutation in fusA gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID477411	Antibacterial activity against MBX-1090-resistant Staphylococcus aureus isolate d20A1 after 16 to 20 hrs by broth microdilution method	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR.
AID581657	Antibacterial activity against normal phenotype Staphylococcus aureus at pH 7.4 after 24 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID324706	Antimicrobial activity against Staphylococcus aureus RN4220 expressing pCU1 gene	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Genetic basis of resistance to fusidic acid in staphylococci.
AID586042	Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type U3 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID261278	Antibacterial activity against Staphylococcus epidermidis CK 5	2006	Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5	Synthesis and biological evaluation of photoaffinity labeled fusidic acid analogues.
AID424588	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH348 (SCV-20) harboring TGA stop codon at nucleotide 244 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID285345	Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus HT20041010 in Mueller-Hinton medium	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID424604	Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH383 (SCV-55) harboring TAA stop codon at nucleotide 139 in rplF gene after 18 to 24 hrs by Etest strip assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID576365	Antibacterial activity against Staphylococcus aureus harboring L461S mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID586044	Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type 4 assessed as percent susceptible isolates by kirby-bauer method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1811	Experimentally measured binding affinity data derived from PDB	1995	Journal of molecular biology, Dec-15, Volume: 254, Issue:5	Steroid recognition by chloramphenicol acetyltransferase: engineering and structural analysis of a high affinity fusidic acid binding site.
AID977610	Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB	1995	Journal of molecular biology, Dec-15, Volume: 254, Issue:5	Steroid recognition by chloramphenicol acetyltransferase: engineering and structural analysis of a high affinity fusidic acid binding site.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	768 (45.42)	18.7374
1990's	235 (13.90)	18.2507
2000's	292 (17.27)	29.6817
2010's	323 (19.10)	24.3611
2020's	73 (4.32)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	5 (23.81%)	5.53%
Trials	117 (6.72%)	5.53%
Reviews	4 (19.05%)	6.00%
Reviews	100 (5.74%)	6.00%
Case Studies	0 (0.00%)	4.05%
Case Studies	175 (10.05%)	4.05%
Observational	0 (0.00%)	0.25%
Observational	6 (0.34%)	0.25%
Other	12 (57.14%)	84.16%
Other	1,344 (77.15%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Trial	Phase	Enrollment	Study Type	Start Date	Status
Pharmacovigilence for Retapamulin: Age-stratified Monitoring of Prescribed Use in the European Union[NCT01153828]		1 participants (Actual)	Observational	2008-11-30	Completed
Six- Versus Twelve-Week Therapy for Non-Surgically-Treated Diabetic Foot Osteomyelitis: A Multicenter Open-Label Controlled Randomized Study[NCT02123628]	Phase 4	40 participants (Actual)	Interventional	2007-06-30	Completed
A Multicentre Study Evaluating the Efficacy of Combining Topical Antibiotic/Steroid/Moisturizer Therapy Compared to Standard of Care in the Treatment of Severe Atopic Dermatitis, a Phase II Randomized, Clinical Trial[NCT03052348]		78 participants (Anticipated)	Interventional	2017-11-01	Not yet recruiting
A Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of Oral Sodium Fusidate (CEM-102) Compared to Oral Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infections[NCT02570490]	Phase 3	716 participants (Actual)	Interventional	2015-11-30	Completed
Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema[NCT03395132]	Phase 3	68 participants (Actual)	Interventional	2018-07-31	Terminated(stopped due to Due to business strategic reasons, LEO Pharma has decided to close down the FCF-38 trial.)
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections[NCT00948142]	Phase 2	198 participants (Actual)	Interventional	2009-08-31	Completed
Topical Treatment With Glucocorticoids to Prevent Hypertrophic Scars and Keloid Due to Central Venous Access in Children[NCT01113125]	Phase 3	60 participants (Anticipated)	Interventional	2010-03-31	Active, not recruiting
A Phase IV Study Comparing Clinical and Bacteriological Efficacy of Fucidin® Cream With Fucidin® Cream Vehicle in the Treatment of Impetigo in Paediatric Patients[NCT00986856]	Phase 4	58 participants (Actual)	Interventional	2004-05-31	Terminated(stopped due to Enrollment failed)
A Randomized, Open Label Study to Compare the Use of the Dermatological Creams Verutex, Eritex and Fisiogel in the Management of Skin Rash Associated With Tarceva Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer.[NCT00718315]	Phase 3	201 participants (Actual)	Interventional	2009-04-30	Completed
A Phase 2, Randomized, DB, Placebo-controlled Study to Determine the Efficacy, Safety and PK Profile of ARV-1801 in Combination With Optimized Background Therapy for the Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis[NCT05641298]	Phase 2	0 participants (Actual)	Interventional	2023-02-10	Withdrawn(stopped due to Corporate finances)
Effectiveness of Sodium Fusidate Ointment Compared to Petrolatum for Wound Healing Following Cauterization: A Double-Blind Randomized Controlled Trial[NCT05353374]		22 participants (Actual)	Interventional	2021-01-01	Completed
[NCT01756924]	Phase 2	14 participants (Actual)	Interventional	2012-12-31	Terminated(stopped due to This study has been terminated; alternative study designs are being considered. Fusidic acid remains available under an Expanded Access Protocol.)
The Healing Effects Of Honey and Hydrogel Products On The Diabetic Foot[NCT03816618]	Early Phase 1	120 participants (Actual)	Interventional	2020-01-01	Completed
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated[NCT02569541]	Phase 2/Phase 3	30 participants (Actual)	Interventional	2015-12-31	Completed
The Efficacy Of Lyclear (Permethrin 5%) Vs Fusidic Acid1% and Synthomycine 5% for Demodex -Blepharitis Treatment, Prospective-Randomized Trial.[NCT03105505]	Phase 4	75 participants (Anticipated)	Interventional	2017-04-28	Enrolling by invitation
Long-term StaphyloCoccus Aureus decolonizAtion in Patients on Home parenteRal nutRition: a randomIzed multicEnter tRial.[NCT03173053]		63 participants (Actual)	Interventional	2018-02-08	Terminated(stopped due to Results interim-analysis)
Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis[NCT05398679]	Phase 4	360 participants (Anticipated)	Interventional	2022-06-01	Not yet recruiting
Prospective Cohort Study on Patients With Tedizolid Prolonged Therapy for Orthopedic Device Infections[NCT03378427]		35 participants (Actual)	Interventional	2018-08-28	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	Units on a scale (Mean)
Fucidin® Cream	-3.9
Fucidin® Cream Vehicle	-1.2

Intervention	Participants (Number)
	Success	Failure
Fucidin® Cream	17	16
Fucidin® Cream Vehicle	1	12

Intervention	Participants (Number)
	Clinical and bacteriological success	Clinical and bacteriological failure
Fucidin® Cream	16	17
Fucidin® Cream Vehicle	1	12

Intervention	percentage of participants (Number)
	Grade 0	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Fisiogel	37.7	39.3	23.0	0	0	0
Stiemicyn	39.7	36.5	22.2	1.6	0	0
Verutex	52.5	39.3	6.6	1.6	0	0

Intervention	Participants (Count of Participants)
	Clinical Success	Clinical Failure	Indeterminate
CEM-102 (Sodium Fusidate)	10	15	5

Intervention	Participants (Count of Participants)
	Treatment Emergent AE (TEAE)	Severe TEAE	TEAE Related to Study Drug	TEAE Leading to Study Discontinuation	TEAE Leading to Study Drug Discontinuation	TE Serious Adverse Event (SAE)	TE SAE with outcome of death	TE SAE Related to Study Drug	TE SAE Leading to Study Discontinuation	TE SAE Leading to Study Drug Discontinuation
CEM-102 (Sodium Fusidate)	29	12	7	9	12	15	0	0	7	9

Article	Year
Hepatotoxicity and hematologic complications induced by fusidic acid in a patient with hepatitis B cirrhosis: A case report. Medicine, Volume: 98, Issue: 45	2019
Flucloxacillin and fusidic acid-associated neutropenia in a patient with periaortic abscess: rare side effects of commonly used antibiotics. BMJ case reports, Mar-25, Volume: 2015	2015
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS computational biology, Volume: 7, Issue: 12	2011
The safety record of fusidic acid in non-US markets: a focus on skin infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Volume: 52 Suppl 7	2011
A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Volume: 52 Suppl 7	2011
Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Volume: 52 Suppl 7	2011
Toxicity of five protein synthesis inhibiting antibiotics and their mixture to limnic bacterial communities. Aquatic toxicology (Amsterdam, Netherlands), Sep-15, Volume: 99, Issue: 4	2010
An in vitro strategy to evaluate the phototoxicity of solar UV at the molecular and cellular level: application to photoprotection assessment. European journal of dermatology : EJD, Volume: 8, Issue: 6	1998
Fusidic acid suppresses nitric oxide toxicity in pancreatic islet cells. Biochemical pharmacology, Oct-07, Volume: 48, Issue: 7	1994
Cultured human fibroblasts as a model for evaluation of potential in vivo toxicity of membrane damaging antibiotics. Chemico-biological interactions, Volume: 29, Issue: 3	1980
Staphylococcal septicaemia complicated by probable cloxacillin neurotoxicity and by jaundice induced by fusidic acid. Scottish medical journal, Volume: 28, Issue: 2	1983
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Pharmacokinetics and Organ Distribution of C-3 Alkyl Esters as Potential Antimycobacterial Prodrugs of Fusidic Acid. ACS infectious diseases, 03-13, Volume: 6, Issue: 3	2020
Pharmacokinetic-pharmacodynamic modelling to investigate in vitro synergy between colistin and fusidic acid against MDR Acinetobacter baumannii. The Journal of antimicrobial chemotherapy, 04-01, Volume: 74, Issue: 4	2019
The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. Drug metabolism and disposition: the biological fate of chemicals, Volume: 44, Issue: 5	2016
Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance. Antimicrobial agents and chemotherapy, Volume: 57, Issue: 1	2013
Ribosome clearance by FusB-type proteins mediates resistance to the antibiotic fusidic acid. Proceedings of the National Academy of Sciences of the United States of America, Feb-07, Volume: 109, Issue: 6	2012
Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Volume: 52 Suppl 7	2011
Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Volume: 52 Suppl 7	2011
Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection. Diagnostic microbiology and infectious disease, Volume: 70, Issue: 1	2011
Pharmacokinetics of fusidic acid and cefepime in heart tissues: implications for a role in surgical prophylaxis. Journal of chemotherapy (Florence, Italy), Volume: 20, Issue: 4	2008
Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile. Chemotherapy, Volume: 53, Issue: 4	2007
Fusidic acid viscous eyedrops--an evaluation of pharmacodynamics, pharmacokinetics and clinical use for UK optometrists. Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists), Volume: 26, Issue: 4	2006
Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics. International journal of antimicrobial agents, Volume: 12 Suppl 2	1999
[Pharmacokinetics of fusidic acid in patients with seriously infected burns]. Pathologie-biologie, Volume: 47, Issue: 5	1999
The pharmacokinetics and protein-binding of fusidic acid in patients with severe renal failure requiring either haemodialysis or continuous ambulatory peritoneal dialysis. The Journal of antimicrobial chemotherapy, Volume: 39, Issue: 6	1997
Intranasal administration of human growth hormone (hGH) in combination with a membrane permeation enhancer in patients with GH deficiency: a pharmacokinetic study. The Journal of clinical endocrinology and metabolism, Volume: 76, Issue: 4	1993
Pharmacokinetics of intravenous fusidic acid in patients with cholestasis. Antimicrobial agents and chemotherapy, Volume: 37, Issue: 3	1993
Pharmacokinetics of fusidic acid after a single dose of a new paediatric suspension. Journal of clinical pharmacy and therapeutics, Volume: 18, Issue: 3	1993
Pharmacokinetics and tolerance of a new film-coated tablet of sodium fusidate administered as a single oral dose to healthy volunteers. The Journal of antimicrobial chemotherapy, Volume: 23, Issue: 3	1989
Pharmacokinetics of sodium fusidate after single and repeated infusions and oral administration of a new formulation. The Journal of antimicrobial chemotherapy, Volume: 25 Suppl B	1990
Pharmacokinetics of fusidic acid in laboratory animals. Laboratory animal science, Volume: 41, Issue: 5	1991
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology, Volume: 96, Issue: 5	2019
Rapid reduction of viruria and stabilization of allograft function by fusidic acid in a renal transplant recipient with JC virus-associated nephropathy. Infection, Volume: 43, Issue: 5	2015
Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance. Antimicrobial agents and chemotherapy, Volume: 57, Issue: 1	2013
A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Volume: 52 Suppl 7	2011
Management of infections of osteoarticular prosthesis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, Volume: 12 Suppl 3	2006
Alternative delivery of insulin via eye drops. Diabetes technology & therapeutics, Volume: 7, Issue: 5	2005
Antidiabetogenic effect of fusidic acid in diabetes prone BB rats: a sex-dependent organ accumulation of the drug is seen. Pharmacology & toxicology, Volume: 91, Issue: 3	2002
Comparative review of topical ophthalmic antibacterial preparations. Drugs, Volume: 61, Issue: 2	2001
Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics. International journal of antimicrobial agents, Volume: 12 Suppl 2	1999
An ocular bioavailability comparison in rabbits of prednisolone acetate after repeated topical applications formulated as a high-viscosity gel and as an aqueous suspension. Acta ophthalmologica Scandinavica, Volume: 74, Issue: 3	1996
A bioavailability comparison in rabbits after a single topical ocular application of prednisolone acetate formulated as a high-viscosity gel and as an aqueous suspension. Acta ophthalmologica Scandinavica, Volume: 74, Issue: 3	1996
Pharmacokinetics of fusidic acid after a single dose of a new paediatric suspension. Journal of clinical pharmacy and therapeutics, Volume: 18, Issue: 3	1993
The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer. Pharmaceutical research, Volume: 11, Issue: 5	1994
Effects of sodium taurodihydrofusidate on nasal absorption of insulin in sheep. Journal of pharmaceutical sciences, Volume: 76, Issue: 5	1987
A study of fucidin uptake in ischaemic tissues. Drugs under experimental and clinical research, Volume: 14, Issue: 10	1988
Rectal absorption enhancement of cefoxitin and desglycinamide arginine vasopressin by sodium tauro-24,25-dihydrofusidate in conscious rats. The Journal of pharmacology and experimental therapeutics, Volume: 251, Issue: 2	1989
Absorption enhancement of intranasally administered insulin by sodium taurodihydrofusidate (STDHF) in rabbits and rats. Pharmaceutical research, Volume: 6, Issue: 10	1989
The effect of sodium tauro-24,25-dihydrofusidate on the nasal absorption of human growth hormone in three animal models. Pharmaceutical research, Volume: 7, Issue: 5	1990
Absorption enhancement of rectally infused insulin by sodium tauro-24,25-dihydrofusidate (STDHF) in rats. Pharmaceutical research, Volume: 7, Issue: 2	1990
Intranasal bioavailability of insulin powder formulations: effect of permeation enhancer-to-protein ratio. Journal of pharmaceutical sciences, Volume: 80, Issue: 8	1991
Pharmacokinetics of fusidic acid in laboratory animals. Laboratory animal science, Volume: 41, Issue: 5	1991
Tolerability and absorption enhancement of intranasally administered octreotide by sodium taurodihydrofusidate in healthy subjects. Pharmaceutical research, Volume: 9, Issue: 1	1992
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Fusidic Acid and Its Major Active Metabolite Penetration into Cerebrospinal Fluid for Assessing Treatment of Intracranial Infections. Chemotherapy, Volume: 68, Issue: 1	2023
Preclinical development of sodium fusidate antibiotic cutaneous spray based on water-free lipid formulation system. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Sep-01, Volume: 176	2022
Synthesis of Fusidic Acid Derivatives Yields a Potent Antibiotic with an Improved Resistance Profile. ACS infectious diseases, 02-12, Volume: 7, Issue: 2	2021
Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration. Antimicrobial agents and chemotherapy, Volume: 60, Issue: 10	2016
Fusidic Acid: A Bacterial Elongation Factor Inhibitor for the Oral Treatment of Acute and Chronic Staphylococcal Infections. Cold Spring Harbor perspectives in medicine, Jan-04, Volume: 6, Issue: 1	2016
An RP-HPLC Method for the Stability-Indicating Analysis of Impurities of Both Fusidic Acid and Betamethasone-17-Valerate in a Semi-Solid Pharmaceutical Dosage Form. Journal of chromatographic science, Volume: 53, Issue: 9	2015
Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance. Antimicrobial agents and chemotherapy, Volume: 57, Issue: 1	2013
Efforts to support the development of fusidic acid in the United States. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Volume: 52 Suppl 7	2011
Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Volume: 52 Suppl 7	2011
Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection. Diagnostic microbiology and infectious disease, Volume: 70, Issue: 1	2011
Mechanical properties and water vapour permeability of film from Haruan (Channa striatus) and fusidic acid spray for wound dressing and wound healing. Pakistan journal of pharmaceutical sciences, Volume: 23, Issue: 2	2010
Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances. Antimicrobial agents and chemotherapy, Volume: 52, Issue: 4	2008
Fusidic acid suspension twice daily: a new treatment schedule for skin and soft tissue infection in children, with improved tolerability. The Journal of dermatological treatment, Volume: 15, Issue: 3	2004
Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, Volume: 37, Issue: 4	2002
Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. International journal of clinical pharmacology and therapeutics, Volume: 37, Issue: 11	1999
Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics. International journal of antimicrobial agents, Volume: 12 Suppl 2	1999
Sordarin inhibits fungal protein synthesis by blocking translocation differently to fusidic acid. The Journal of biological chemistry, Aug-06, Volume: 274, Issue: 32	1999
[Pharmacokinetics of fusidic acid in patients with seriously infected burns]. Pathologie-biologie, Volume: 47, Issue: 5	1999
[Postoperative mediastinitis due to methicillin resistant Staphylococcus epidermidis with low sensitivity to vancomycin]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, Volume: 4, Issue: 12	1997
The pharmacokinetics and protein-binding of fusidic acid in patients with severe renal failure requiring either haemodialysis or continuous ambulatory peritoneal dialysis. The Journal of antimicrobial chemotherapy, Volume: 39, Issue: 6	1997
Treatment of endocarditis with teicoplanin: a retrospective analysis of 104 cases. The Journal of antimicrobial chemotherapy, Volume: 38, Issue: 3	1996
Intranasal administration of human growth hormone (hGH) in combination with a membrane permeation enhancer in patients with GH deficiency: a pharmacokinetic study. The Journal of clinical endocrinology and metabolism, Volume: 76, Issue: 4	1993
Pharmacokinetics of intravenous fusidic acid in patients with cholestasis. Antimicrobial agents and chemotherapy, Volume: 37, Issue: 3	1993
Pharmacokinetics of fusidic acid after a single dose of a new paediatric suspension. Journal of clinical pharmacy and therapeutics, Volume: 18, Issue: 3	1993
Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock. Immunology, Volume: 85, Issue: 4	1995
Determination of sodium fusidate and fusidic acid in dosage forms by high-performance liquid chromatography and a microbiological method. Journal of pharmaceutical sciences, Volume: 71, Issue: 11	1982
Acute osteomyelitis and septic arthritis in children. A simple approach to treatment. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, Jan-28, Volume: 65, Issue: 4	1984
Antibiotics and human monocyte function. I. Chemotaxis. Acta pathologica, microbiologica, et immunologica Scandinavica. Section B, Microbiology, Volume: 95, Issue: 5	1987
Pharmacokinetics and tolerance of a new film-coated tablet of sodium fusidate administered as a single oral dose to healthy volunteers. The Journal of antimicrobial chemotherapy, Volume: 23, Issue: 3	1989
Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. Klinische Wochenschrift, Jan-04, Volume: 69, Issue: 1	1991
Levels of fusidic acid in skin blister fluid and serum after repeated administration of two dosages (250 and 500 mg). The British journal of dermatology, Volume: 126, Issue: 6	1992
Mechanisms of resistance to fusidic acid in Staphylococcus aureus. Journal of general microbiology, Volume: 96, Issue: 2	1976
Amplification of chloramphenicol resistance transposons carried by phage P1Cm in Escherichia coli. Molecular & general genetics : MGG, Oct-03, Volume: 176, Issue: 2	1979
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
A Randomized Study Evaluating Oral Fusidic Acid (CEM-102) in Combination With Oral Rifampin Compared With Standard-of-Care Antibiotics for Treatment of Prosthetic Joint Infections: A Newly Identified Drug-Drug Interaction. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Dec-15, Volume: 63, Issue: 12	2016
Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration. Antimicrobial agents and chemotherapy, Volume: 60, Issue: 10	2016
Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model. PloS one, Volume: 11, Issue: 6	2016
In vitro drug interactions of gallates with antibiotics in Staphylococcus Aureus. Frontiers in bioscience (Elite edition), 01-01, Volume: 2, Issue: 2	2010
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). Journal of medicinal chemistry, Jun-12, Volume: 51, Issue: 11	2008
In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrobial agents and chemotherapy, Volume: 47, Issue: 1	2003
Extracellular and intracellular killing in neutrophil granulocytes of Staphylococcus aureus with rifampicin in combination with dicloxacillin or fusidic acid. The Journal of antimicrobial chemotherapy, Volume: 43, Issue: 3	1999
Effect of vancomycin and teicoplanin alone or in combination with fusidic acid or amikacin against methicillin-resistant staphylococci. Journal of chemotherapy (Florence, Italy), Volume: 9, Issue: 1	1997
Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. The Journal of antimicrobial chemotherapy, Volume: 39, Issue: 2	1997
Intranasal administration of human growth hormone (hGH) in combination with a membrane permeation enhancer in patients with GH deficiency: a pharmacokinetic study. The Journal of clinical endocrinology and metabolism, Volume: 76, Issue: 4	1993
Fusidic acid alone or in combination with vancomycin for therapy of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy, Volume: 37, Issue: 11	1993
In-vitro antibacterial activity of fusidic acid alone and in combination with other antibiotics against methicillin-sensitive and -resistant Staphylococcus aureus. The Journal of antimicrobial chemotherapy, Volume: 34, Issue: 6	1994
Classification of polyene antibiotics according to their synergistic effect in combination with bleomycin A2 or fusidic acid. Antimicrobial agents and chemotherapy, Volume: 18, Issue: 2	1980
[In vitro activity of fusidic acid in combination with various antibiotics against Staphylococcus epidermidis]. Pathologie-biologie, Volume: 36, Issue: 5 Pt 2	1988
In-vitro activity of ciprofloxacin combined with either fusidic acid or rifampicin against Staphylococcus aureus. The Journal of antimicrobial chemotherapy, Volume: 23, Issue: 3	1989
Antibacterial activity of teicoplanin and vancomycin in combination with rifampicin, fusidic acid or fosfomycin against staphylococci on vein catheters. Scandinavian journal of infectious diseases. Supplementum, Volume: 72	1990
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Intervention	Days (Median)
Fisiogel	16.0
Stiemicyn	15.0
Verutex	15.0

Substance	Description	Relationhip Strength	Studies	Trials	Classes	Roles
oxybenzone	[no description available]	medium	1	1	hydroxybenzophenone; monomethoxybenzene	dermatologic drug; environmental contaminant; protective agent; ultraviolet filter; xenobiotic
octocrylene	[no description available]	medium	2	1	diarylmethane
avobenzone	[no description available]	medium	6	3	dihydrochalcones
bemotrizinol	[no description available]	medium	2	0	methoxybenzenes
triazoles	[no description available]	medium	2	0	1,2,3-triazole
pyrimidine dimers	[no description available]	medium	1	0
titanium	[no description available]	medium	2	1	titanium group element atom
2,2',4,4'-tetrahydroxybenzophenone	[no description available]	medium	1	0
titanium dioxide	[no description available]	medium	2	1	titanium oxides	food colouring
4-aminobenzoic acid	[no description available]	medium	1	0	aminobenzoic acid; aromatic amino-acid zwitterion	allergen; Escherichia coli metabolite; plant metabolite
oxalates	[no description available]	medium	1	0
avobenzone, ecamsule, octocrilene drug combination	[no description available]	medium	2	0
camphor, (+-)-isomer	[no description available]	medium	11	2	bornane monoterpenoid; cyclic monoterpene ketone	plant metabolite
drometrizole	[no description available]	medium	1	0	triazoles
2-nitro-4-phenylenediamine	[no description available]	medium	1	0	C-nitro compound; primary amino compound
caffeine	[no description available]	medium	1	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
sulisobenzone	[no description available]	medium	1	0	benzophenones
ensulizole	[no description available]	medium	1	0	benzimidazoles
disodium phenyl dibenzimidazole tetrasulfonate	[no description available]	medium	1	0
urocanic acid	[no description available]	medium	1	1	urocanic acid	human metabolite
octylmethoxycinnamate	[no description available]	medium	3	2	cinnamate ester
enzacamene	[no description available]	medium	1	1
beta-thujaplicin	[no description available]	low	0	0	cyclic ketone; enol; monoterpenoid	antibacterial agent; antifungal agent; antineoplastic agent; antiplasmodial drug; plant metabolite
moxisylyte	[no description available]	low	0	0	monoterpenoid
cantharidin	[no description available]	low	0	0	cyclic dicarboxylic anhydride; monoterpenoid	EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; herbicide
linalool	[no description available]	low	0	0	monoterpenoid; tertiary alcohol	antimicrobial agent; fragrance; plant metabolite; volatile oil component
thymol	[no description available]	low	0	0	monoterpenoid; phenols	volatile oil component
citronellal	[no description available]	low	0	0	aldehyde; monoterpenoid	antifungal agent; metabolite
linalyl acetate	[no description available]	low	0	0	acetate ester; monoterpenoid
menthyl anthranilate	[no description available]	low	0	0	monoterpenoid
citronellol	[no description available]	low	0	0	monoterpenoid	plant metabolite
citronellyl acetate	[no description available]	low	0	0	acetate ester; monoterpenoid	plant metabolite
beta-cyclocitral	[no description available]	low	0	0	monoterpenoid	bacterial metabolite
citronellic acid	[no description available]	low	0	0	medium-chain fatty acid; monoterpenoid; monounsaturated fatty acid	flavouring agent; plant metabolite
2-thymotic acid	[no description available]	low	0	0	monoterpenoid
Mecamylamine hydrochloride	[no description available]	low	0	0	monoterpenoid
moxisylyte hydrochloride	[no description available]	low	0	0	monoterpenoid
fencamfamine	[no description available]	low	0	0	monoterpenoid
bornaprine	[no description available]	low	0	0	monoterpenoid
nopinone	[no description available]	low	0	0	monoterpenoid

fusidic acid

Description

Cross-References

Synonyms (139)

Roles (3)

Drug Classes (7)

Protein Targets (18)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (59)

Molecular Functions (41)

Ceullar Components (30)

Bioassays (497)

Research

Studies (1,691)

Study Types

Clinical Trials (18)

Trial Overview

Trial Outcomes

The Actual Change in Total Severity Score From Baseline to End of Treatment (LOCF).

Number of Patients With Bacteriological Success at EOT

Number of Patients With Bacteriological Success at Visit 2

Number of Patients With Bacteriological Success at Visit 3

Number of Patients With Clinical Success (Marked Improvement or Completely Cleared) and Bacteriological Success (Eradication) at End of Treatment (EOT).

Number of Patients With Clinical Success at EOT

Number of Patients With Clinical Success at Visit 2

Number of Patients With Clinical Success at Visit 3

Percentage of Participants Who Develop Skin Rash

Percentage of Participants With Erythema

Percentage of Participants With Pain

Percentage of Participants With Pruritus

Time to Appearance of Skin Rash

Percentage of Participants With Erythema Stratified by Severity Grade

Percentage of Participants With Pain Stratified by Severity Grade

Percentage of Participants With Pruritus Stratified by Severity Grade

Percentage of Participants With Skin Rash Stratified by Severity Grade

Clinical Success at 12 Months

Clinical Success at 15 Months

Clinical Success at 18 Months

Clinical Success at 21 Months

Clinical Success at 24 Months

Clinical Success at 6 Months

Clinical Success at 9 Months

Safety and Tolerability

Related Drugs (2,133)

Related Conditions (1,915)

Research Highlights

Safety/Toxicity (11)

Pharmacokinetics (21)

Bioavailability (22)

Dosage (35)

Interactions (17)